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TheObjective: Hyperglycemia worsens outcomes in critical illness. This randomized,
double-blind, placebo-controlled clinical trial tested whether insulin treatment of
hyperglycemia during cardiopulmonary bypass would reduce neurologic, neuro-
ophthalmologic, and neurobehavioral outcomes after coronary artery bypass graft-
ing.
Methods: Three hundred eighty-one nondiabetic patients undergoing isolated cor-
onary artery bypass grafting were given infusions of insulin or placebo when their
blood glucose concentration exceeded 100 mg/dL during cardiopulmonary bypass.
The primary outcome measure was the combined incidence of new neurologic,
neuro-ophthalmologic, or neurobehavioral deficits or neurologic death observed at
4 to 8 days postoperatively. This same measure was assessed secondarily at 6 weeks
and 6 months. Length of hospital stay was also compared as a secondary assessment.
Results: The 2 groups were well matched at baseline. The insulin-treated group had
significantly lower blood glucose concentrations during bypass. Sixty-six percent of
subjects in the insulin-treated group and 67% of subjects in the control group
demonstrated a new or worsening neurologic, neuro-ophthalmologic, or neurobe-
havioral deficit or neurologic death at the 4- to 8-day assessment. Outcomes were
also similar in the 2 groups at 6 weeks (37% and 39% incidence, respectively) and
6 months (30% and 25%, respectively). Median lengths of stay were 7 and 6 days,
respectively, in the treatment and control groups. None of these outcome differences
was statistically significant.
Conclusion: Attempted control of hyperglycemia during cardiopulmonary bypass
had no significant effect on the combined incidence of neurologic, neuro-ophthal-
mologic, or neurobehavioral deficits or neurologic death and failed to shorten the
length of hospital stay. These results do not contradict those of other studies
showing that aggressive control of hyperglycemia in the postoperative period will
improve outcome.
After coronary artery bypass grafting (CABG) with cardiopulmonary bypass(CPB), 6% of patients have adverse neurologic outcomes.1 In the past, at least50% of patients undergoing CPB displayed at least temporary deterioration in
psychomotor performance, and a similar fraction of patients demonstrated biochemical
evidence of neural injury.2,3 The incidence of frank stroke has been as frequent as 5%
in some series.2 Despite continuing investigation, fundamental questions remain unan-
swered. One of these questions, that of the value of prevention of hyperglycemia during
CPB, was prompted by evidence linking adverse outcomes to intraoperative embolism
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We therefore performed a randomized clinical trial in nondia-
betic patients undergoing CABG to determine whether at-
tempting to control hyperglycemia during CPB with insulin
infusion, compared with placebo infusion, would reduce the
combined incidence of new post-CABG neurologic, neuro-
ophthalmologic, and neuropsychologic deficits. Secondarily,
we sought to determine whether attempted blood glucose con-
trol during CPB would reduce the length of postoperative
hospital stay. Some results unrelated to the primary hypothesis
of this trial have been reported previously.6-8
Methods
The study was reviewed and approved by the Wake Forest Uni-
versity School of Medicine Institutional Review Board. Written
informed consent was obtained from each prospective research
subject. All subjects were English-speaking adults between the
ages of 35 and 80 years scheduled to undergo CABG with CPB.
Subjects with a history of diabetes mellitus treated by diet, oral
hypoglycemic agents, or insulin were excluded. Subjects with a
history of a neurodegenerative disease (eg, Alzheimer or Parkinson
disease), major depressive disorder, or psychosis in the past 5
years were also excluded. Subjects underwent a neurologic and
neuro-ophthalmologic history and physical examination and also
underwent neuropsychologic testing on the afternoon or evening
before the operation. These examinations usually were conducted
in the patient’s hospital room by one of two nurse clinicians.
Generally, the same examiner conducted all examinations of a
given subject.
Day of the Operation
All subjects were premedicated with morphine, 0.1 mg · kg1
administered intramuscularly, and, in most cases, oral lorazepam,
50 g · kg1. Anesthesia consisted of intravenous fentanyl, 25 to
50 g · kg1, and midazolam, 0.1 to 0.3 mg · kg1. After neuro-
muscular blockade (in most cases intravenous pancuronium, 0.1-
0.15 mg · kg1), intubated subjects were ventilated with oxygen-
enriched air. Enflurane at inhaled concentrations of 1% or less was
sometimes used to supplement general anesthesia. Intraoperative
hemodynamic aberrations were treated according to protocol with
intravenous fluid, vasodilators, vasoconstrictors, positive ino-
tropes, atropine, or -adrenergic blockers, as appropriate. No in-
travenous dextrose was administered intraoperatively on a routine
basis. Dextrose was present in cardioplegic solutions (see Table
E1). Corticosteroids were not administered to these patients.
Blood Glucose Control
Arterial blood samples were obtained at 15-minute intervals during
CABG to measure blood glucose concentrations with a handheld
glucose meter (Accucheck; Roche Diagnostics, Basel, Switzer-
land). In the control arm, blood glucose concentrations were mea-
sured and recorded for later analysis. A saline infusion was peri-
odically adjusted to preserve blinding. For subjects randomized to
blood glucose control, after induction of anesthesia, insulin infu-
sion at 2 U/h in a 70-kg patient was started when the blood glucose
concentration exceeded 100 mg/dL. If 2 U/h failed to reduce the
blood glucose concentration to approximately 100 mg/dL, the
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dose (to 4 U/h). Insulin infusion was adjusted as required at
15-minute intervals by the study nurse. Only the study nurse was
aware of the glucose concentrations or whether insulin was being
infused. When blood glucose concentrations decreased to less than
100 mg/dL, the insulin infusion was discontinued. When blood
glucose concentrations decreased to less than 70 mg/dL, 100 to
200 mL of dextrose 5% was administered at the direction of the
study nurse. After the patient was weaned from CPB, the insulin
infusion was weaned over 30 to 45 minutes. Serum potassium
concentrations were measured every 30 minutes intraoperatively
and were maintained between 3.5 and 5.5 mEq/L.
CPB was conducted with a membrane oxygenator and a buff-
ered crystalloid priming solution to which no glucose was added.
Mean arterial pressure was pharmacologically maintained between
50 and 90 mm Hg. Subjects were cooled to a core temperature of
27°C and then rewarmed to 37.5°C. The left ventricle was vented
through the right superior pulmonary vein, and the aorta was
vented (when indicated) through a needle vent. Arterial inflow and
cardiotomy suction filters were used. PaO2 was maintained at 150
to 200 mm Hg, and PaCO2 was maintained at 38 to 42 mm Hg by
the alpha-stat approach. Either crystalloid or (more commonly)
blood cardioplegic solution was delivered antegradely. Cardiople-
gia components are described in Table E1. During rewarming, the
inflow blood temperature never exceeded 38.5°C, and the gradient
between inflow blood temperature and core temperature never
exceeded 10°C.
Outcome Measurement Timing
A brief screening neurologic examination was conducted to doc-
ument neurologic events that occurred on postoperative days 1 to
4. Subjects underwent a final, in-hospital, full neurologic, neuro-
ophthalmologic, and neuropsychologic evaluation between post-
operative days 4 and 8. Subjects underwent the full neurologic,
neuro-ophthalmologic, and neuropsychologic battery at 1 month
(3-6 weeks) and again at 5.5 to 6.5 months. This testing took place
in a quiet office.
Primary Outcome
The primary outcome variable used to define treatment effect in
this clinical trial was any new or worsening neurologic or neuro-
ophthalmologic deficit, neurologic death, or a decrease of at least
20% in 2 or more neuropsychologic test results at the 4- to 8-day
postoperative examination.
Comprehensive Neurologic Examination
The comprehensive neurologic and neuro-ophthalmologic examina-
tion was performed by a certified neurologic nurse clinician and
confirmed by a neurologist. On postoperative days 4 to 8, at 3 to 6
weeks, and at 5.5 to 6.5 months postoperatively, the entire neurologic
examination was repeated, and results were scored according to the
National Institutes of Health stroke scale and Stroke Data Bank
criteria.9
Neuropsychologic Assessment
We defined clinically important deterioration in performance as an
individual subject’s decrease from preoperative to postoperative
score of 20%10,11 on a test. Neuropsychologic evaluation was
ovember 2005
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weeks, and at 5.5 to 6.5 months. The standard neuropsychologic
battery was used.
The Visual Reaction Time test was used only to discriminate
between deterioration in performance because of ischemic neuro-
logic deficits from deterioration caused by visual impairment.
Sample Size Calculations
We anticipated that at least 50% of the patients would experience
one or more of these deficits at the 4- to 8-day assessment. A
sample size of 186 in each group was necessary to detect a 17%
difference in deficits (0.5 to 0.33 or 0.5 to 0.67) with 90% power
at the 5% 2-sided level of significance.
Patients were randomized to the treatment groups with equal
probability by blocked randomization. Block sizes of varying
length were determined randomly. Treatment assignments were
generated by a randomization computer program.
Statistical Testing
The primary outcome was compared in the 2 groups by the Fisher
exact test or the 2 test where appropriate. Blood glucose mea-
surements were compared over time by a mixed-effects, repeated-
measures model. SAS (version 8; SAS Institute, Cary, NC) was
used for all calculations.
Interim Monitoring
An independent Data Safety and Monitoring Board met once a
year to examine interim results. Statistical guidelines (on the basis
of modifications of procedures discussed by O’Brien and Flem-
ing12 and Lan and colleagues13) were used during the interim
reviews.
Results
A total of 381 subjects completed preoperative screening
and neuropsychologic evaluations and were enrolled in
the study. The 2 groups were well matched on the basis
of sex, age, and race, as shown in Table 1. Subjects in the
2 study groups were distributed similarly by operating
surgeon (Table 1).
Baseline medical characteristics were similar in the 2
groups, with the exception of a more frequent history of
congestive heart failure in the insulin-treated group (9.6%
vs 4.2%). A history of cerebrovascular disease was present
in 16.6% of placebo-treated patients and 15.4% of insulin-
treated patients. Five percent of patients in both groups
demonstrated a stenosis of greater than 50% in one or more
of the right or left, internal, or common carotid arteries by
Doppler examination. The preoperative neuropsychologic
examination scores were similar in the 2 treatment arms.
There were no significant between-group differences (Table
E2). Few subjects in either group had preoperative neuro-
ophthalmologic or neurologic abnormalities (Table E3).
The duration of CPB (121  36 vs 125  37 minutes)
and the duration of aortic clamping (57  22 vs 59  22
minutes) were similar in the placebo- and insulin-treated
groups, respectively. Most patients (80% of placebo-treated
The Journal of Thoracic anand 82% of insulin-treated patients) received blood cardio-
plegia. The remainder received crystalloid cardioplegia.
All patients in the insulin-treated group demonstrated a
blood glucose concentration of greater than 100 mg/dL and
received insulin. Blood glucose concentrations were main-
tained at significantly (P  .01) reduced values in the
insulin-treated group compared with those in the placebo-
treated group, as shown in Figure 1. Initial blood glucose
concentrations on arrival in the intensive care unit (ICU)
were similar in the placebo-treated and insulin-treated
groups (179  60 vs 178  57 mg/dL, respectively). One
patient in the placebo-treated group and no patients in the
insulin-treated group had a blood glucose measurement of
less than 80 mg/dL in the first 24 hours in the ICU. During
the first 24 hours in the ICU, all patients had a blood glucose
measurement of at least 100 mg/dL. Many patients had at
least one blood glucose measurement of greater than 200
mg/dL (placebo-treated group, 40%; insulin-treated group,
42%). Only a few patients had at least one blood glucose
measurement of greater than 300 mg/dL (placebo-treated
group, 8%; insulin-treated group, 6%). One percent of pa-
tients in both groups had at least one blood glucose mea-
surement of greater than 400 mg/dL during the first 24 hours
in the ICU.
Most adverse events (including death) had a similar
incidence in the 2 groups (Table 2). During postoperative
evaluations, the 2 groups were similar (Table 3). Neuro-
ophthalmologic, neurologic, and neuropsychologic deficits
were most common at the 4- to 8-day examination and less
common thereafter (Table 4). There was no significant
between-group difference in the primary outcome (Table 4).
Length of stay was similar in the 2 groups (median of 6
days and range of 3-85 days in the placebo-treated group
and median of 7 days and range of 3-51 days in the insulin-
treated group). The total number of emboli counted ultra-
sonically in the left common carotid artery was similar in
the 2 groups (median of 105 and range of 1-2563 in the
placebo-treated group and median of 108 and range of
1-14,613 in the insulin-treated group).
To determine whether increasing blood glucose concen-
trations per se might associate with worsening neurologic
outcomes, we divided subjects in the placebo-treated group
into 2 equal classes on the basis of the degree of hypergly-
cemia they demonstrated during CPB. The cutoff point
between the 2 groups was determined by calculating the
area under the blood glucose versus time curve for each
placebo-treated subject and then rank ordering them. We
found that subjects ranked in the upper 50% of ranks for
areas under the curve (these were the patients with more
consistently increased blood glucose measurements) were
no more likely than those in the lower 50% of ranks to have
new or worsening neurologic, neurophthalmologic, or neu-
robehavioral deficit or neurologic death (68% vs 71% at 4-8
d Cardiovascular Surgery ● Volume 130, Number 5 1319.e3
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5.5-6.5 months, respectively).
Discussion
Administration of insulin during CPB failed to improve
outcomes, as assessed by the combined incidence of neuro-
ophthalmologic, neurologic, or neuropsychologic deficits or
neurologic death in patients without diabetes mellitus un-
dergoing CABG. Insulin administration failed to improve
either short-term or long-term outcome and failed to reduce
length of hospital stay. Moreover, in the control group,
subjects with greater blood glucose measurements during
CPB had no worse outcome than subjects with more nearly
TABLE 1. Patient characteristics and distribution by treatm
Placebo
(n  193)*
Sex
Male 158 (82)
Female 35 (18)
Race
White 183 (95)
Black 10 (5)
Age (y)
50 29 (15)
51-60 57 (30)
61-70 73 (38)
70 34 (18)
Surgeon
A 32 (17)
B 34 (18)
C 50 (26)
D 46 (24)
Others 31 (16)
Marital status
Never married 3 (1.6)
Currently married 150 (77.7)
Separated-divorced 18 (9.3)
Widowed 20 (10.4)
Living together 1 (0.5)
Other 1 (0.5)
Education
Not a high school graduate 84 (43.5)
High school/vocational/business/some college 88 (45.6)
College graduate 21 (10.9)
Smoking
Ever smoked regularly 153 (79)
Currently smokes 31 (21)
Height (cm), mean (SD) 175 (9)
Weight (kg), mean (SD) 84 (18)
Body mass index, mean (SD) 27.4 (5.2)
SD, Standard deviation. *Maximum number for each treatment arm; num
(percentage), except as noted. †Some lumping (never  living together normal blood glucose measurements.
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during CPB, despite insulin infusion. It is likely that we
would have achieved better glucose control had we ad-
ministered larger doses of insulin in response to hyper-
glycemia. Studies completed after we initiated this pro-
tocol have shown that attempting complete glucose
control during CPB might be hazardous because of the
frequent postoperative hypoglycemia and hypokalemia
that will result.14
Our selection of 100 mg/dL as our target value was based
on the diabetes literature. Since the results of the Diabetes
Control and Complications Trial were published, there has
been an increased emphasis on avoidance of hyperglycemia
arm
Insulin
(n  188)*
All
(n  381)
P value,
2
P value,
Fisher exact test
150 (80) 308 (81) .61 .70
38 (20) 73 (19)
180 (96) 363 (95) .48 .62*
7 (4) 17 (5)
34 (18) 63 (17) .56
53 (28) 110 (29)
61 (32) 134 (35)
40 (21) 74 (19)
32 (17) 64 (17) .99
33 (18) 67 (18)
46 (25) 96 (25)
49 (26) 95 (25)
28 (15) 59 (16)
3 (1.6) 6 (1.6) .49†
150 (79.8) 300 (78.7)
22 (11.7) 40 (10.5)
12 (6.4) 32 (8.4)
1 (0.5) 2 (0.5)
0 (0.0) 1 (0.3)
74 (39.4) 158 (41.5) .39
85 (45.2) 173 (45.4)
29 (15.4) 50 (13.1)
143 (76) 296 (78)
28 (20) 59 (20)
173 (10) 174 (10)
81 (16) 174 (10)
27.3 (4.6) 83 (17)
aries by 1 because of missing values. All data are provided as number
r) to compute this P value.ent
ber vin diabetic subjects.15 Our negative results do not argue
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CPB.16,17 Numerous studies have shown value in the con-
trol of hyperglycemia in patients undergoing CABG and
with other critical illnesses.18-20 Some recent studies also
Figure 1. Box plots of blood glucose measurements in t
The boxes include the 25th to 75th percentile values
vertical lines define the 5th and 95th percentile values.
(shaded bars) had significantly (P < .001) reduced blo
(all measurements between “on CPB” and “X-clamp o
by a mixed-effects, repeated-measures model. Cann, C
of cooling; Temp 28, arrival of nasopharyngeal temper
crossclamp; Start Warm, rewarming begins; Temp 34,
Off, removal of aortic crossclamp; Off CPB, 5 minutes
TABLE 2. Adverse events by treatment arm
Placebo,
n (%)
Death 5 (2.6)
Stroke 3 (1.5)
Cardiac arrest requiring CPR 1 (0.5)
Arrhythmia requiring cardioversion 4 (2.1)
Hypoglycemia (blood glucose 70 mg/dL) 12 (6.2)
Hyperkalemia (K 5.5 mEq/L) 44 (22.7)
Rehospitalization 28 (16.2)CPR, Cardiopulmonary resuscitation.
The Journal of Thoracic andemonstrate an association between hyperglycemia and ad-
verse outcomes after ischemic stroke.21
Our data argue that blood glucose concentrations as great
as 200 mg/dL do not appear to be deleterious during CPB in
treatment groups at the time of various surgical events.
thicker lines denote the 50th percentile value. The
dot denotes the mean value. The insulin-treated group
lucose measurements during cardiopulmonary bypass
clusive) compared with the control group (open bars)
lation; on CPB, initiation of CPB; Start Cool, initiation
at nadir of 28°C; Aortic XClamp, application of aortic
pharyngeal temperature reaches 34°C; Aortic XClamp
separation from CPB.
Insulin,
n (%)
Total,
n (%)
Fisher exact test,
P value
6 (3.2) 11 (2.9) .77
5 (2.6) 8 (2.1) .50
3 (1.6) 4 (1) .37
2 (1.1) 6 (1.6) .69
22 (11.7) 34 (8.9) .07
35 (18.6) 79 (20.7) .38
19 (11.6) 47 (13.9) .27he 2
. The
The
od g
ff,” in
annu
ature
naso
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appear to be warranted. These results and conclusions are
consistent with an earlier study of glucose-insulin-potas-
sium (GIK) during CABG.22
Nevertheless, our study has several obvious limitations.
We made no attempt to control blood glucose concentra-
tions at times other than CPB in these subjects who did not
have diabetes. We hypothesized that brain injury associated
with coronary surgery occurs mostly during CPB, and we
focused on control of blood glucose during that critical
period. It very well could be important to control blood
glucose concentrations after CPB in patients who have
sustained a brain insult, and our results do not address that
possibility. We also did not study patients having any of the
several forms of “beating-heart” surgery without CPB, and
our results might not apply to those patients. After this study
was completed, our usual practice changed, and we no
longer routinely cool patients who are undergoing CABG. It
is possible that tight glucose control might offer greater
benefit to patients having lesser degrees of hypothermic
TABLE 3. Impaired performance on neuropsychologic test
4-8 d
Placebo
(n  156)
Insulin
(n  152)
Mean visual reaction 38 31
Trails A 28 29
Trails B 37 40
Grooved Pegboard
Dominant hand 27 36
Nondominant hand 29 41
Symbol Digit 30 23
Letter Cancellation 36 25
Finger Tapping
Dominant hand 12 15
Nondominant hand 13 12
Nonverbal Memory 12 15
Rey Auditory Verbal 22 29
TABLE 4. New or worsening deficits by treatment arm an
Treatment arm
4-8 d, n
(%)
Neuro-ophthalmologic Placebo 14 (8)
Insulin 20 (12)
Neurologic Placebo 42 (24)
Insulin 34 (21)
Neuropsychologic Placebo 98 (63)
Insulin 98 (65)
Neurologic death Placebo 120 (67)
Insulin 115 (66)
Combined 235 (67)All data are given as percentage incidence (no. of observations).
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undergoing correction of congenital heart disease has shown
no detrimental effect on outcome of increased intraoperative
blood glucose concentrations.23
The most important limitation of our study is that we
specifically excluded diabetic patients from our study, and
therefore our results might not apply to that population.
Diabetes is associated with worse outcomes after CABG.24
We suggest that insulin infusion should be used to control
blood glucose concentrations in diabetic subjects undergo-
ing CABG. Our exclusion of diabetic subjects led to a
disproportionate reduction in the number of female subjects.
A recent study has compared tight glycemic control with
infusion of GIK solution to intermittent subcutaneous injec-
tions of insulin in diabetic patients undergoing CABG.25 In this
trial 30% of these diabetic patients were using insulin, and the
remainder were using either oral agents or dietary adjustments
for glucose control preoperatively. In this study GIK was
discontinued on initiation of CPB and not restarted until the
aorta was unclamped. In other words, it studied GIK at times
exceeding 20% of baseline) by treatment arm (%)
3-6 wk 5.5-6.5 mo
Placebo
n  166)
Insulin
(n  153)
Placebo
(n  128)
Insulin
(n  121)
16 16 21 18
11 13 15 12
9 14 10 9
2 7 1 3
3 7 2 2
3 3 3 3
10 13 4 4
5 5 3 2
4 3 5 2
7 7 7 6
19 15 6 10
it
3-6 wk, n
(%)
5.5-6.5 mo, n
(%)
GEE treatment·time,
P value
5 (3) 5 (4) .714
11 (8) 11 (10)
30 (20) 7 (6) .062
22 (16) 15 (13)
35 (22) 22 (18) .665
31 (21) 16 (13)
62 (39) 31 (25) .5
55 (37) 34 (30)
117 (38) 65 (27)ing (
(d visovember 2005
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specific times we infused insulin. Moreover, this trial focused
on those patients who were excluded from our study. Interest-
ingly, the GIK group had a reduced incidence of atrial fibril-
lation, a shorter length of hospital stay, and a survival advan-
tage compared with the control group.
Our outcome measures are similar to those used in other
tests of neuroprotective drugs and neuroprotective strategies
during cardiac surgery.26-28 Our selection of neuropsycho-
logic tests was consistent with recommendations from con-
sensus panels.29 Our criterion for neuropsychologic deficit
defines a distinctly abnormal score for each subject on the
basis of the subject’s baseline performance. Because of
learning-practice effects, it would be expected that healthy
control subjects not having operations would show at worst
the same score as at baseline and more often an improved
score.
In conclusion, insulin infusion for attempted blood glu-
cose control during CPB failed to improve either short-term
or long-term neurologic outcomes, and it failed to shorten
length of stay. Even though tight control of blood glucose
concentration improves outcomes in many classes of pa-
tients with critical illness, attempted tight control of blood
glucose with insulin infusion appears not to produce brain
protection in patients undergoing CABG with CPB. Perhaps
the opinion expressed in a recent editorial by Loepke and
Spaeth,30 that children are unlike adults in the failure of
hyperglycemia to worsen outcome, might be incorrect. It
might be that neither adults nor children derive benefit from
strategies to prevent mild intraoperative hyperglycemia in
patients who do not have diabetes mellitus.
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Cardiopulmonary Support and Physiology Butterworth et alTABLE E1. Contents of cardioplegic solutions
Induction dose Subsequent doses
Blood cardioplegia*
THAM 2.1 g 71.6 mL 1.6 g 53.3 mL
Glutamate 32.4 g 44.3 mL 24.4 g 33.3 mL
Aspartate 27.7 g 44.3 mL 20.8 g 33.3 mL
CPD 17.8 mL 13.3 mL
KCl 26.6 mEq 13.3 mL 0.0 mEq 0.0 mL
Lidocaine 50.0 mg 2.5 mL 50.0 mg 2.5 mL
D5W 88.1 mL 66.8 mL
282.5 mL 202.5 mL
Cystalloid cardioplegia
D5LR 1000 mL 1000 mL
NaHCO3 25 mEq 25 mEq
Heparin 2000 U 2000 U
KCl 25 mEq 10 mEq
THAM, Tris-hydroxyaminomethane; CPD, citrate-phosphate-dextrose; D5W, 5% dextrose in water; D5LR, 5% dextrose in lactated Ringer’s solution. *Blood
cardioplegic solutions were mixed 1:4 with heparinized blood before administration.
TABLE E2. Baseline neuropsychologic assessment scores by treatment arm
Test
Placebo
(n  193)*
Insulin
(n  188)*
All
(n  381)
Visual reaction time (s) 1.6 (0.9) 1.6 (0.8) 1.6 (0.9)
Trails A corrected time (s) 62 (23) 61 (22) 62 (22)
Trails B corrected time (sec) 127 (50) 122 (48) 124 (49)
Grooved Pegboard total time (s)
Dominant hand 93 (31) 90 (27) 92 (29)
Nondominant hand 101 (29) 95 (26) 98 (28)
Symbol Digit total time (s) 214 (52) 211 (53) 213 (52)
Letter Cancellation total time (s) 136 (37) 137 (37) 137 (37)
Finger Tapping (mean no. of taps)
Dominant hand 32 (8) 32 (8) 32 (8)
Nondominant hand 29 (7) 29 (7) 29 (7)
Nonverbal memory (total correct) 16 (3) 16 (3) 16 (3)
Rey Auditory Verbal (total score) 46 (13) 48 (13) 47 (13)
*Maximum n for each treatment arm; n varies by no more than 6 because of missing values (except for Trails B, in which n  175 for arm 1 and n  173
for arm 2, and for Rey, in which n  175 for arm 1 and n  174 for arm 2).
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Butterworth et al Cardiopulmonary Support and PhysiologyTABLE E3. Baseline distribution of preoperative neurologic
and neuro-ophthalmologic abnormalities by treatment arm
No. of abnormalities
Placebo
(n  188), %
Insulin
(n  185), %
All
(n  373), %
Neurologic
0 147 (78.2) 156 (84.3) 303 (81.2)
1 36 (19.2) 26 (14.1) 62 (16.6)
2 5 (2.7) 2 (1.1) 7 (1.9)
3 0 (0.0) 1 (0.5) 1 (0.3)
Neuro-ophthalmologic
0 168 (89.4) 164 (89.6) 332 (89.5)
1 18 (9.6) 19 (10.4) 37 (10.0)
2 2 (1.1) 0 (0.0) 2 (0.5)
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